Phreesia, Inc. (PHR) told investors that its healthcare platform was driving growth, that AI tools were expanding, and that visibility remained strong. But according to the complaint, demand in key revenue streams was already slowing, and visibility was weakening.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
A federal lawsuit alleges Phreesia misled investors about the strength of its pharmaceutical marketing business and concealed slowing demand before the company cut revenue guidance, after which its stock fell about 27%.
The complaint, filed in the United States District Court for the District of Delaware, alleges that Phreesia, Inc. (NYSE: PHR) and two of its top executives made materially false and misleading statements about the company’s fiscal year 2027 revenue outlook and the durability of its Network Solutions segment. According to the complaint, after repeatedly maintaining or updating guidance during the class period and introducing fiscal year 2027 guidance, Phreesia disclosed on March 30, 2026, that it was significantly cutting its revenue forecast. The stock fell approximately 27% the following trading day, dropping from $11.41 to $8.38 per share, as investors digested a guidance reduction from a range of $545 million to $559 million down to $510 million to $520 million.
Investors who purchased PHR shares during the class period and suffered losses may want to learn more about their eligibility and legal options.
What Phreesia Does and Why It Matters
Phreesia provides an integrated SaaS-based software and payment platform serving the healthcare industry in the United States and Canada. Its platform offers solutions including appointment optimization, referral management, AI-enabled workflows, digital check-in, clinical and administrative data capture, patient payment processing, and analytics.
A critical component of the company’s business, as described in the complaint, is its Network Solutions segment. Through this segment, pharmaceutical and life sciences companies direct marketing spending to reach patients across Phreesia’s healthcare provider network. According to the complaint, defendants described Network Solutions as a key growth driver, and analysts later referred to it as one of Phreesia’s fastest-growing revenue lines in recent years.
How Phreesia Allegedly Misled Investors About Its Growth Outlook
The complaint centers on allegations that Phreesia’s leadership painted an overly optimistic picture of the company’s trajectory while internal conditions were deteriorating. Specifically, the lawsuit alleges that CEO Chaim Indig and CFO Balaji Gandhi repeatedly assured investors that Network Solutions would drive sustained revenue growth for fiscal year 2027, even as demand from pharmaceutical clients was slowing and visibility into committed spending was weakening.
Throughout the class period, defendants maintained or raised revenue guidance on multiple occasions. They characterized pharmaceutical marketing commitments as a durable growth driver, pointed to new products and a recent acquisition as additional catalysts, and expressed confidence in the selling season. The complaint alleges that these representations created a false impression that management possessed reliable information supporting the company’s long-term outlook while minimizing the risks posed by declining demand.
According to the complaint, the Individual Defendants, by virtue of their positions as CEO and CFO, had actual knowledge of or access to non-public information concerning slowing demand in Network Solutions, yet they repeatedly and affirmatively represented that the segment’s expansion would drive revenue growth and overall profitability.
Investors following this case can stay informed about developments as the litigation progresses.
What Executives Told Investors Before the Guidance Cut
The complaint highlights a series of statements from Phreesia’s leadership during earnings calls and guidance announcements throughout the class period.
On May 28, 2025, when Phreesia reported first-quarter fiscal year 2026 results and maintained revenue guidance of $472 million to $482 million, Gandhi told analysts that the company’s visibility into the year was “the same as it was last year at this time” and that there was nothing unusual to call out regarding Network Solutions’ performance. Indig described the fiscal year as “off to a strong start” and pointed to the company’s strong ROI and growing scale as reasons why pharmaceutical clients would continue to direct marketing dollars to Phreesia’s platform.
On September 4, 2025, the company reaffirmed revenue guidance, announced the AccessOne acquisition, and reported a 25% growth rate in Network Solutions. Gandhi told analysts the company was “in a similar place we were last year at this time” regarding the selling season and that the team was “performing really well.” Indig highlighted VoiceAI and the company’s expanded reach as positioning Phreesia well for the future. Later, in December, defendants also pointed to HCP marketing as an emerging growth opportunity.
On December 8, 2025, defendants narrowed and raised their fiscal year 2026 revenue outlook to $479 million to $481 million and introduced fiscal year 2027 revenue guidance of $545 million to $559 million, representing a 14% to 16% increase. Gandhi reiterated that Network Solutions would be the fastest-growing segment and highlighted expected contributions from new products, including post-script engagement and HCP marketing. Indig described these emerging products as enabling Phreesia “to sustain growth and enhance stakeholder value” and positioned the company’s HCP marketing capabilities as a “multibillion-dollar” opportunity.
How the Alleged Truth Came to Light
According to the complaint, the corrective disclosure occurred on March 30, 2026, after the market closed. Phreesia announced its fourth quarter and full fiscal year 2026 results and significantly lowered its fiscal year 2027 revenue guidance to a range of $510 million to $520 million, down from the prior range of $545 million to $559 million.
The company disclosed that Network Solutions clients were committing lower spending in the second half of fiscal year 2027 than defendants had anticipated in December. Phreesia cited worsening visibility into pharmaceutical manufacturer spending commitments and brand-specific dynamics, including the impact of regulatory policies. Indig acknowledged that “segments of the life sciences industry are facing challenges” and that this was creating “more variability” in financial forecasting. Gandhi described the booking environment as “very fluid” and identified specific areas of weakness, including vaccines and public health agency spending.
Analysts reacted sharply. Truist Securities cut its price target from $24 to $11, noting the guidance reduction was “a surprising magnitude of change given that the company previously characterized their preliminary outlook as a ‘conservative’ starting point.” J.P. Morgan lowered its target from $24 to $16 and downgraded the stock to Neutral, citing “worsening visibility into pharma DTC budgets.” Citizens downgraded Phreesia to Market Perform, questioning the company’s ecosystem thesis.
On March 31, 2026, Phreesia’s stock price fell from $11.41 to $8.38 per share, a decline of approximately $3.03 per share, or about 27%.
What This Means for Phreesia Shareholders
The complaint alleges a straightforward pattern: management repeatedly presented Network Solutions as a strong growth driver, introduced fiscal year 2027 revenue targets, and then lowered guidance after allegedly concealed weakness in pharmaceutical marketing commitments emerged. The guidance cut reduced the low end of the range by $35 million and the high end by $39 million.
For investors who purchased PHR shares between May 8, 2025, and March 30, 2026, the alleged inflation in the stock price was sustained by management’s repeated affirmations of growth and visibility. When the corrective disclosure arrived, the complaint alleges, the market rapidly repriced the stock to reflect the information that had previously been withheld. The 27% single-day decline and multiple analyst downgrades underscore the significance of the gap between what investors were told and what the company ultimately reported.
The Legal Claims Against Phreesia
The complaint alleges violations of federal securities laws, specifically Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. These provisions prohibit the making of materially false or misleading statements in connection with the purchase or sale of securities. The plaintiff alleges that defendants made statements about Phreesia’s revenue outlook, Network Solutions’ growth, and pharmaceutical marketing demand that were materially false and misleading when made, or that omitted material facts necessary to make the statements not misleading.
The complaint also brings claims under Section 20(a) of the Exchange Act against CEO Chaim Indig and CFO Balaji Gandhi, alleging that, as senior officers, they exercised control over the company and are therefore liable for the alleged misrepresentations.
Investors who purchased or otherwise acquired PHR shares between May 8, 2025, and March 30, 2026, are encouraged to learn more about their rights and the July 13, 2026, lead plaintiff deadline.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.